Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IMPATH to list on EASDAQ:

This article was originally published in Clinica

Executive Summary

IMPATH, a source of patient-specific cancer diagnostic and prognostic information, is to list on the Brussels-based EASDAQ stock exchange. The New York-based company has a database with over 475,000 analysed cancer cases. "We believe this listing will raise our commercial profile among important European clinical, medical and healthcare management decision-makers - as well as international investors," said Dr Anu Saad, IMPATH's president and CEO. "A major element of our approach is to form key strategic alliances and to identify partnerships and complementary acquisitions in Europe." The company serves over 4,500 physicians in over 1,740 hospitals and 290 oncology practices.

You may also be interested in...

Novavax May Seek COVID-19 Vaccine Emergency Authorization In US Based On UK Data

With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.

Biogen And Sage On Plans To Build A Brain Franchise Together

The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.

US FDA Allows Dry-Heat Systems For Mask Deep Cleaning

The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts